Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TAK-653 in Healthy Subjects
NCT02561156Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Aug 2015
- Primary completion
- Sep 2017
- Modality
- Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of osavampator in major depressive disorder (MDD) (13 arms), sponsored by Neurocrine Biosciences. Primary endpoints: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event at Day 31, Percentage of Participants Who Discontinued the Treatment Due to an Adverse Event at Day 31 and 5 more. Started Aug 2015; status: completed.
02
Drugs
osavampator
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT02561156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02561156.